RenovoRx, Inc. (RNXT) stock

RNXTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30146% above fair value

$1.16−0.06 (-4.92%)

Close on Nov 12, 2026Market cap $52.35MP/E –Yield –

RenovoRx cash

Cash and short-term investments held at the end of each period.

RenovoRx's cash was $10.40M at Sep 30, 2026. For fiscal 2025 it was $7.02M, down 1.8% from the year before. The highest annual figure on record is $15.19M in fiscal 2021.

Annual cash

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$7.02M	-1.8%
FY2024	Dec 31, 2024	$7.15M	+509.9%
FY2023	Dec 31, 2023	$1.17M	-81.7%
FY2022	Dec 31, 2022	$6.40M	-57.9%
FY2021	Dec 31, 2021	$15.19M	+746.4%
FY2020	Dec 31, 2020	$1.80M	–

Quarterly cash

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	$10.40M	+3.6%
Q2 FY2026	Jun 30, 2026	$9.48M	-23.0%
Q1 FY2026	Mar 31, 2026	$12.36M	-15.2%
Q4 FY2025	Dec 31, 2025	$7.02M	-1.8%
Q3 FY2025	Sep 30, 2025	$10.04M	+5.0%
Q2 FY2025	Jun 30, 2025	$12.31M	+4.9%
Q1 FY2025	Mar 31, 2025	$14.58M	+232.2%
Q4 FY2024	Dec 31, 2024	$7.15M	+509.9%
Q3 FY2024	Sep 30, 2024	$9.56M	+196.4%
Q2 FY2024	Jun 30, 2024	$11.74M	+97.2%
Q1 FY2024	Mar 31, 2024	$4.39M	+17.9%
Q4 FY2023	Dec 31, 2023	$1.17M	-81.7%
Q3 FY2023	Sep 30, 2023	$3.23M	-60.2%
Q2 FY2023	Jun 30, 2023	$5.95M	-44.9%
Q1 FY2023	Mar 31, 2023	$3.72M	-71.6%
Q4 FY2022	Dec 31, 2022	$6.40M	-57.9%
Q3 FY2022	Sep 30, 2022	$8.10M	-54.3%
Q2 FY2022	Jun 30, 2022	$10.80M	+501.7%
Q1 FY2022	Mar 31, 2022	$13.12M	–
Q4 FY2021	Dec 31, 2021	$15.19M	–
Q3 FY2021	Sep 30, 2021	$17.73M	–
Q4 FY2020	Dec 31, 2020	$1.80M	–